Expert Review of Endocrinology & Metabolism,
Journal Year:
2025,
Volume and Issue:
unknown, P. 1 - 12
Published: April 12, 2025
In
2023,
metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD)
was
introduced
following
fatty
(MAFLD).
Both
aim
to
address
the
limitations
of
nonalcoholic
(NAFLD).
This
review
analyzes
similarities
and
differences
between
MAFLD
MASLD,
focusing
on
their
impacts
epidemiology,
diagnosis,
stigma,
related
diseases.
Current
evidence
suggests
that
criteria
effectively
identify
individuals
at
higher
risk
through
a
good
balance
sensitivity
specificity.
Moreover,
is
more
generalizable
term
easily
understood
globally.
The
transition
from
NAFLD
MASLD
marks
significant
advance
in
understanding
within
hepatology.
identifies
homogeneous
cohort
patients
with
due
dysfunction
provides
valuable
framework
for
holistic,
patient-centered
management
strategies
consider
various
contributing
factors
improve
health
outcomes.
Behavioral Sleep Medicine,
Journal Year:
2025,
Volume and Issue:
unknown, P. 1 - 14
Published: March 13, 2025
Objectives
The
relationship
between
actigraphy-derived
sleep
parameters,
day-to-day
deviations
in
and
metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD),
a
new
definition
of
nonalcoholic
fatty
(NAFLD),
remains
unclear.
We
aimed
to
explore
the
associations
duration,
midpoint,
variability
irregularity
with
MASLD
risk.
Annals of Medicine,
Journal Year:
2025,
Volume and Issue:
57(1)
Published: April 6, 2025
Liver
steatosis
and
fibrosis
increase
the
predicted
10-year
atherosclerotic
cardiovascular
disease
(ASCVD)
risk,
though
roles
of
chronic
inflammation
metabolic
dysregulation
remain
unclear.
This
cross-sectional
study
quantitatively
assesses
this
association
evaluates
mediating
effects
inflammation.
In
study,
we
enrolled
6110
adults
from
ten
communities
in
Canton,
China.
Hepatic
were
assessed
using
vibration-controlled
transient
elastography
(VCTE)
through
controlled
attenuation
parameter
(CAP)
liver
stiffness
measurement
(LSM),
while
ASCVD
risk
was
calculated
China-PAR
project
model.
Associations
between
CAP/LSM
values
analyzed.
Mediation
analysis
quantified
high-sensitivity
C-reactive
protein
(hs-CRP),
homeostasis
model
assessment
insulin
resistance
(HOMA-IR),
remnant
cholesterol
(RC),
non-high-density
lipoprotein
(non-HDL-C).
The
main
statistical
methods
used
included
logistic
regression,
restricted
cubic
splines
(RCS)
analysis,
interaction
calculations,
mediation
to
examine
relationships
mediators.
population
had
a
mean
age
50.1
years
(SD
=
9.7),
with
3927
females
(64.3%)
2183
males
(35.7%).
Additionally,
808
participants
(13.2%)
type
2
diabetes,
1911
(31.3%)
hypertension.
Compared
first
CAP
quartile
(Q1),
higher
quartiles
showed
increased
odds
ratios
(OR)
for
moderate
high
risk:
1.14
(0.89,
1.45),
1.37
(1.08,
1.73),
2.44
(1.93,
3.10).
hs-CRP
HOMA-IR
mediated
CAP's
link
proportions
15.40%
27.37%.
RC
non-HDL-C
at
7.12%
6.26%.
Among
patients
hepatic
(CAP
≥
248
dB/m),
LSM
Q4
significantly
than
those
Q1
(OR
2.22,
[1.52,
3.25]),
2.62%
13.75%,
respectively.
associated
hs-CRP,
HOMA-IR,
RC,
non-HDL-C.
ABSTRACT
Exosome‐like
nanovesicles
derived
from
plants
(PENs)
harbor
a
spectrum
of
bioactive
compounds,
including
proteins,
lipids,
nucleic
acids
(such
as
miRNAs
and
mRNAs),
offering
therapeutic
advantages
for
variety
diseases.
This
investigation
assesses
the
utility
pomegranate‐derived
exosome‐like
(PNVs)
in
both
preventing
treating
complications
such
liver
damage
increased
intestinal
permeability
found
Metabolic
Dysfunction‐Associated
Steatotic
Liver
Disease
(MASLD).
Utilizing
Transmission
Electron
Microscopy
(TEM)
Nanoparticle
Tracking
Analysis
(NTA),
we
successfully
isolated
PNVs
characterized
their
structural
properties.
Upon
administration
live
model,
these
were
efficiently
distributed
to
critical
organs,
intestines,
demonstrating
biocompatibility
by
avoiding
toxic
effects.
Remarkably,
vesicles
enriched
with
ellagic
acid,
known
its
strong
antioxidant
capabilities.
In
controlled
MASLD
mouse
study,
treatment
significantly
lowered
serum
endotoxin
levels,
reinforced
barrier
functions,
altered
gut
microbiota
profile
favorably.
Furthermore,
application
reduced
oxidative
stress
presence
fibrosis
markers
normal
levels.
These
results
indicate
that
could
be
viable
option
addressing
MASLD,
enhancing
integrity,
reducing
injury,
diminishing
through
modulation
gut‐liver
axis.
Expert Review of Endocrinology & Metabolism,
Journal Year:
2025,
Volume and Issue:
unknown, P. 1 - 12
Published: April 12, 2025
In
2023,
metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD)
was
introduced
following
fatty
(MAFLD).
Both
aim
to
address
the
limitations
of
nonalcoholic
(NAFLD).
This
review
analyzes
similarities
and
differences
between
MAFLD
MASLD,
focusing
on
their
impacts
epidemiology,
diagnosis,
stigma,
related
diseases.
Current
evidence
suggests
that
criteria
effectively
identify
individuals
at
higher
risk
through
a
good
balance
sensitivity
specificity.
Moreover,
is
more
generalizable
term
easily
understood
globally.
The
transition
from
NAFLD
MASLD
marks
significant
advance
in
understanding
within
hepatology.
identifies
homogeneous
cohort
patients
with
due
dysfunction
provides
valuable
framework
for
holistic,
patient-centered
management
strategies
consider
various
contributing
factors
improve
health
outcomes.
